For ambitious enterprises operating within the Irish state, fiscal strategy and technological innovation are fundamentally intertwined. Maximizing your return on innovation requires an exact understanding of how corporate incentives evolve under the Taxes Consolidation Act 1997 (TCA).

A significant transformation has occurred within Ireland’s fiscal landscape. Following legislative updates introduced via the Finance Act, the Research and Development (R&D) Corporation Tax Credit has officially escalated to 35% for qualifying expenditure.

At Intax.ie, we view this statutory increase not merely as an administrative adjustment, but as a high-value tool designed to blunt operational costs and accelerate corporate liquidity. For financial controllers, CFOs, and founders structuring their development roadmaps, navigating these updated Revenue.ie mechanisms is essential to optimizing cash flow.

1. The Mechanics of the 35% Escalation

The R&D tax credit has undergone a rapid, multi-year transition. Historically positioned at 25%, the baseline rate climbed to 30% before reaching its current peak statutory rate:

• The Baseline Rate: 35% on all qualifying incremental expenditure.

• The Payment Framework: In strict alignment with sections 766C and 766D of the TCA, the credit operates as a fully payable incentive rather than a simple corporate tax reduction. It is delivered directly to the company in three annual installments (structured as 50% in year one, 30% in year two, and 20% in year three), ensuring that early-stage, pre-revenue entities can receive cash injections even in the absence of an immediate Corporation Tax liability.

This corporate incentive serves as a major fiscal offset; you can read our comprehensive analysis on Ireland’s 12.5% vs. 15% Corporation Tax landscape to see how baseline structures are shifting for trading companies in the state.

R&D TAX CREDIT EVOLUTION SUMMARY
Historical Base Rate	25%
Prior Threshold	30%
Current Statutory Rate	35%

2. Monetisation: The New €87,500 First-Instalment Threshold

For scaling businesses, timing is everything. The real value of an R&D claim often hinges on how quickly tax credits can be converted back into operational capital.

To support corporate liquidity, Revenue has updated the mechanism governing the first annual instalment. The first-instalment threshold has been expanded from €75,000 to €87,500.

Under this enhanced rule, if your total eligible R&D credit claim falls below €87,500, the entirety of that credit is payable in Year 1, bypassing the standard 3-year instalment split. For larger claims exceeding this cap, the first instalment is calculated as the greater of €87,500 or 50% of the total credit value, ensuring maximum immediate cash flow back into your development cycles.

3. Operational Simplification: The 95% Employee Rule

Historically, one of the most significant administrative burdens during a Revenue R&D audit was the granular tracking of staff hours. Companies were required to meticulously apportion individual employee salaries down to the exact percentage of time spent on qualifying research versus standard operational duties.

To eliminate this friction, an administrative simplification measure has been introduced in the underlying Tax and Duty Manual guidelines:

The 95% Rule: Where an employee performs at least 95% of their duties in the direct carrying on of qualifying R&D activities, 100% of that employee’s emoluments can be included as qualifying expenditure.

This updates the reporting architecture substantially. It removes the need for micro-apportionment for full-time research personnel, drastically simplifying internal record-keeping while safeguarding your claim against retrospective compliance challenges. Maintaining clean digital accounting records is vital for this level of audit readiness; discover more in our roadmap on Mastering VAT in Ireland’s Digital Economy.

4. Capital Expenditure: Laboratories and Qualifying Infrastructure

The scope of qualifying expenditure extends beyond software code and personnel costs. Infrastructure directly serving your research and development teams is heavily incentivized under Section 766D.

Revenue eBrief guidance (specifically aligned with eBrief No. 085/26) explicitly clarifies that expenditure incurred on the construction or refurbishment of a qualifying building includes specialized laboratory environments. If a building or structure is designed and constructed to be used wholly and exclusively for the carrying on of qualifying R&D activities, the capital expenditure can be brought within the credit framework, allowing firms to recover over a third of their structural development costs. Note that any space used as an office or for purposes ancillary to an office remains statutorily excluded from “relevant expenditure” calculations.

The Intax.ie Verdict: Architecture Over Administration

Ireland’s enhanced 35% R&D credit framework represents one of the most aggressive sovereign incentives for innovation globally. However, the premium rate comes with a requirement for supreme data integrity.

To successfully defend a 35% claim, your technical documentation must clearly demonstrate that the activities meet the statutory definition of scientific or technological advancement, while your financial records must withstand transaction-level scrutiny.

Is your company maximizing its return on innovation? Do not allow legacy accounting methods to under-value your research and development assets. Contact the Intax.ie team today to align your corporate workflows with the newest R&D frameworks.